학술논문
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Document Type
Article
Author
Berset, Ingrid P; Fevang, Bjørg TS; Florholmen, Jon; Kalstad, Synøve; Mørk, Nils J; Ryggen, Kristin; Tveit, Kåre S; Sæther, Sigrun K; Gulbrandsen, Bjørn; Hagfors, Jon; Waksvik, Kenneth; Warren, David; Henanger, Karoline J.; Asak, Øivind; Baigh, Somyeh; Blomgren, Ingrid M; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein O; Gjesdal, Clara G; Grandaunet, Berit H J; Hansen, Inger M; Hatten, Ingvild S H; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S; Krogh, Jan; Kruse, Julia R; Ljoså, Maud-Kristine A; Midtgard, Irina P; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon U; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine A; Skjetne, Kristine; Strand, Eldri K; Stray, Hilde; Stray, Njaal; Torp, Roald; Vold, Cecilia; Ystrøm, Carl M; Zettel, Camilla C; Jørgensen, Kristin K; Olsen, Inge C; Goll, Guro L; Lorentzen, Merete; Bolstad, Nils; Haavardsholm, Espen A; Lundin, Knut E A; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore K
Source
In The Lancet 10-16 June 2017 389(10086):2304-2316
Subject
Language
ISSN
0140-6736